chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Vaccine: VARZOS, VARZOS
Symptoms: Herpes zoster, Vaccination failure
Clinical narrative: Suspected Vaccination failure; got both shots just like they said and got Shingles anyway; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (Verbatim: Suspected Vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: got both shots just like they said and got Shingles anyway). The outcome of the vaccination failure and shingles were not reported.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine and Shingles vaccine.     The company considered the vaccination failure and shingles to be unrelated to Shingles vaccine and Shingles vaccine.   Additional Information: GSK Receipt Date: 24-FEB-2025 This case was reported by a patient via interactive digital media. The patient got both shots just like they said and got them anyway, both shots made sick. The patient guess it was a damned. This case was considered as suspected vaccination failure as details regarding time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting.; Sender's Comments: Vaccination failure is a listed event which, due to the following criteria (insufficient information provided about the clinical description, details regarding the completion of primary vaccination schedule, time to onset and laboratory confirmation of disease) is considered unrelated to GSK Shingles vaccine.  Herpes zoster is an unlisted event which is considered unrelated to GSK Shingles vaccine.
Vaccine: VARZOS, VARZOS
Symptoms: Herpes zoster, Vaccination failure
Clinical narrative: Suspected vaccination failure; shingles again; Shingles; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine and the 1st dose of Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant), shingles (Verbatim: shingles again) and shingles (Verbatim: Shingles). The outcome of the vaccination failure was not reported and the outcome of the shingles was not resolved and the outcome of the shingles was resolved.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine and Shingles vaccine. It was unknown if the reporter considered the shingles to be related to Shingles vaccine.     The company considered the vaccination failure, shingles and shingles to be unrelated to Shingles vaccine and Shingles vaccine.   Additional Information: GSK Receipt Date: 24-FEB-2025 This case was reported by a patient via interactive digital media. The patient had the first vaccine as soon as he/she was old enough and got shingles. The moment they were cleared received the newer 2 dose vaccine and currently have shingles again. This case was considered as suspected vaccination failure as details regarding time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting.; Sender's Comments: Vaccination failure is a listed event which, due to the following criteria (insufficient information provided about the clinical description, details regarding the completion of primary vaccination schedule, time to onset and laboratory confirmation of disease) is considered unrelated to GSK Shingles vaccine.  Herpes zoster is an unlisted event which is considered unrelated to GSK Shingles vaccine. US-GSK-US2025AMR024379:same patient  Case created in error, Deleted
Age: 0.17
Sex: F
Vaccine: HEP, HEP, HEP, HEP
Symptoms: Extra dose administered, Inappropriate schedule of product administration
Clinical narrative: accidentally administered an adult dose of Engerix-B to a 19 year old patient; accidentally administered an adult dose of Engerix-B to a 19 year old patient; 1st on August 18th 2005 and 4th on Feb 6 2006; 1st on August 18th 2005 and 3rd on December 5th 2005; 1st on August 18th 2005 and 2nd on October 13th 2005; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult product administered to child in a 9-week-old female patient who received HBV (Engerix B adult) (batch number 5JX2E, expiry date 15-DEC-2026) for prophylaxis.   Co-suspect products included Hepatitis B vaccine for prophylaxis, Hepatitis B vaccine for prophylaxis and Hepatitis B vaccine for prophylaxis.   Concomitant products included HEPATITIS B VACCINE (HEPATITIS B).   On 17-FEB-2025, the patient received the 5th dose of Engerix B adult. On 06-FEB-2006, the patient received the 4th dose of Hepatitis B vaccine. On 05-DEC-2005, the patient received the 3rd dose of Hepatitis B vaccine. On 13-OCT-2005, the patient received the 2nd dose of Hepatitis B vaccine. On 13-OCT-2005, an unknown time after receiving Hepatitis B vaccine, the patient experienced drug dose administration interval too long (Verbatim: 1st on August 18th 2005 and 2nd on October 13th 2005). On 05-DEC-2005, the patient experienced drug dose administration interval too short (Verbatim: 1st on August 18th 2005 and 3rd on December 5th 2005). On 06-FEB-2006, the patient experienced extra dose administered (Verbatim: 1st on August 18th 2005 and 4th on Feb 6 2006). On 17-FEB-2025, the patient experienced adult product administered to child (Verbatim: accidentally administered an adult dose of Engerix-B to a 19 year old patient) and accidental overdose (Verbatim: accidentally administered an adult dose of Engerix-B to a 19 year old patient). The outcome of the adult product administered to child, accidental overdose, extra dose administered, drug dose administration interval too short and drug dose administration interval too long were not applicable.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 17-FEB-2025 The patient received 2nd dose, which was later than the recommended interval, which led to lengthening of vaccination schedule. The patient received 3rd dose, which was earlier than the recommended interval, leading to shortening of vaccination schedule. The patient received 4th dose of Hepatitis B, which was an extra dose administered. The reporter stated that they accidentally administered an adult dose of Engerix-B to a 19 year old patient, which led to adult product administered to child and accidental overdose. The reporter did not have lot number or expiration date for any of the 4 prior doses, brand name not provided.
Age: 1.0
Sex: M
Vaccine: HIBV
Symptoms: Needle issue
Clinical narrative: needle broke in the patient's leg during Hiberix administration; This non-serious case was reported by a physician via call center representative and described the occurrence of needle stick/puncture in a 1-year-old male patient who received Hib (Hiberix) (batch number BE9G7, expiry date 15-JUL-2026) for prophylaxis.   On 19-FEB-2025, the patient received Hiberix. On 19-FEB-2025, less than a day after receiving Hiberix, the patient experienced needle stick/puncture (Verbatim: needle broke in the patient's leg during Hiberix administration). The outcome of the needle stick/puncture was not applicable.   It was unknown if the reporter considered the needle stick/puncture to be related to Hiberix.     It was unknown if the company considered the needle stick/puncture to be related to Hiberix.   Additional Information: GSK Receipt Date: 20-FEB-2025 The physician asked how to proceed after the needle broke in the patient's leg during Hiberix administration. The vaccine administration facility was the same as primary reporter.
Age: 1.0
Sex: F
Vaccine: HEPA
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: accidentally administered an adult presentation of Havrix to a 12 month old patient on February 21st 2025; accidentally administered an adult presentation of Havrix to a 12 month old patient on February 21st 2025; This non-serious case was reported by a nurse via call center representative and described the occurrence of accidental overdose in a 12-month-old female patient who received HAV (Havrix adult) (batch number T9TL9, expiry date 05-DEC-2025) for prophylaxis.   On 21-FEB-2025, the patient received the 1st dose of Havrix adult. On 21-FEB-2025, an unknown time after receiving Havrix adult, the patient experienced accidental overdose (Verbatim: accidentally administered an adult presentation of Havrix to a 12 month old patient on February 21st 2025) and adult product administered to child (Verbatim: accidentally administered an adult presentation of Havrix to a 12 month old patient on February 21st 2025). The outcome of the accidental overdose and adult product administered to child were not applicable.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 21-FEB-2025 Licensed practical nurse stated that they accidentally administered an adult presentation of Havrix to a 12 month old patient, which led to accidental overdose, adult product administered to child.  The reporter refused to provide initials and date of birth of the patient. The vaccine administration facility was the same as primary reporter.
Age: 17.0
Sex: M
Vaccine: HEP
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: seventeen year old patient received an adult dose of Engerix-B; seventeen year old patient received an adult dose of Engerix-B; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult product administered to child in a 18-year-old male patient who received HBV (Engerix B adult) (batch number 5JX2E, expiry date 14-DEC-2026) for prophylaxis.   On 25-NOV-2024, the patient received Engerix B adult. On 25-NOV-2024, an unknown time after receiving Engerix B adult, the patient experienced adult product administered to child (Verbatim: seventeen year old patient received an adult dose of Engerix-B) and overdose (Verbatim: seventeen year old patient received an adult dose of Engerix-B). The outcome of the adult product administered to child and overdose were not applicable.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 21-FEB-2025 The reporter reported that a seventeen year old patient received an adult dose of Engerix B last year, which led to adult product administered to child and overdose. The reporter added now this patient was 18 years old and asked if the patient needs to receive another dose, and wanted to know was the patient covered.
Vaccine: HEPA
Symptoms: Expired product administered
Clinical narrative: Administration of expired dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of expired vaccine used in a patient who received HAV (Havrix 720) (batch number Y3ME2, expiry date 25-FEB-2025) for prophylaxis.   On 25-FEB-2025, the patient received Havrix 720. On 25-FEB-2025, an unknown time after receiving Havrix 720, the patient experienced expired vaccine used (Verbatim: Administration of expired dose). The outcome of the expired vaccine used was not applicable.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 25-FEB-2025 The reporter reported that the patient had given expired hep A vaccine just 2 day later from the expiration day which led to expired vaccine used. The reporter had to re-vaccinated the patient or not. This adverse event was received via Webform. No further details provided.
Age: 73.0
Sex: M
Vaccine: DTAPIPV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: he was supposed to received Tdap (Boostrix), unfortunately the medical assistant gave him the Dtap (Kinrix); Administration to a 73 year old patient; This non-serious case was reported by a nurse via call center representative and described the occurrence of wrong vaccine administered in a 73-year-old male patient who received DTPa-IPV (Kinrix) (batch number 42Y93, expiry date 05-JUN-2026) for prophylaxis.   Co-suspect products included DTPa (Reduced antigen) (Boostrix) for prophylaxis.   On 24-FEB-2025, the patient received Kinrix. On an unknown date, the patient received Boostrix. On 24-FEB-2025, an unknown time after receiving Kinrix and Boostrix, the patient experienced wrong vaccine administered (Verbatim: he was supposed to received Tdap (Boostrix), unfortunately the medical assistant gave him the Dtap (Kinrix)) and inappropriate age at vaccine administration (Verbatim: Administration to a 73 year old patient). The outcome of the wrong vaccine administered and inappropriate age at vaccine administration were not applicable.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 25-Feb-2025 There was an error yesterday with a vaccine that was administered. The patient was supposed to received Tdap (Boostrix), unfortunately the medical assistant gave him the Dtap, the reporter believe is the Kinrix which led to wrong vaccine administered and  inappropriate age at vaccine administration. The reporter need to know if that was going to cause the patient any issue. The Vaccine Administration Facility is the same as Primary Reporter.
Sex: M
Vaccine: HEPAB
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Patient received second dose of Twinrix late; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 52-year-old male patient who received HAB (Twinrix) (batch number B9279, expiry date 12-SEP-2026) for prophylaxis.   Previously administered products included Twinrix (received 1st dose of Twinrix on 6th May 2023 with batch number 2PG309 and expiry date 19th September 2025).   On 09-JAN-2025, the patient received the 2nd dose of Twinrix. On 09-JAN-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Patient received second dose of Twinrix late). The outcome of the drug dose administration interval too long was not applicable.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 25-FEB-2025 The reporter wanted to know how the second dose should have been administered. The vaccine administration facility was the same as primary reporter. The patient received 2nd dose of Twinrix, later than the recommended interval, which led to lengthening of vaccinations schedule. This is 1 of 4 linked cases reported by the same reporter.; Sender's Comments:  US-GSK-US2025023741:same reporter US-GSK-US2022160192:same reporter US-GSK-US2020191512:same reporter
Sex: F
Vaccine: COVID19
Symptoms: Disability, Hypersensitivity, Mast cell activation syndrome, Postural orthostatic tachycardia syndrome
Clinical narrative: Mast Cell Activation Syndrome (MCAS); became disabled; Allergic reactions to covid-19 vaccine; Postural Orthostatic Tachycardia Syndrome (POTS); This spontaneous report received from a health care professional concerned a female patient of unspecified age. The patient's height and weight were not reported. Age at time of vaccination was unknown.  The patient's concurrent conditions included: flu, ivf, and recurring ruptured ovarian cysts.  The patient received janssen covid-19 vaccine (suspension for injection, route of admin not reported, batch number: Unknown) dose and frequency not reported, administered on 2021, additional dosage information included: dose series 1, for covid-19 prophylaxis. The batch number was not reported. The company is unable to perform follow up. No concomitant medications were reported.  On 2021, the patient experienced mast cell activation syndrome (mcas), became disabled, allergic reactions to covid-19 vaccine, and postural orthostatic tachycardia syndrome (pots). (dose series 1). It was reported that patient experienced: The patient had an allergic reaction to the vaccine, after the allergic reaction to the COVID vaccine the patient developed Mast Cell Activation Syndrome (MCAS), Postural Orthostatic Tachycardia Syndrome (POTS), food allergies, food sensitivities, allergic to makeup, allergic to hair dye, and became disabled. The action taken with janssen covid-19 vaccine was not applicable.  The patient had not recovered from mast cell activation syndrome (mcas), became disabled, allergic reactions to covid-19 vaccine and postural orthostatic tachycardia syndrome (pots).  This report was serious (other medically important condition).; Sender's Comments: V0-  Mast cell activation syndrome , disability, Drug hypersensitivity, : Insufficient information is available to make a causality assessment. Therefore, this event is considered unclassifiable.
Sex: M
Vaccine: COVID19
Symptoms: Feeling drunk
Clinical narrative: After second moderna covid-19 shot whenever he drinks coffee, dairy, consume red meat, he feels "drunk."; This spontaneous case was reported by a patient and describes the occurrence of FEELING DRUNK (After second moderna covid-19 shot whenever he drinks coffee, dairy, consume red meat, he feels "drunk.") in a male patient of an unknown age who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received second dose of SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) 1 dosage form. On an unknown date, the patient experienced FEELING DRUNK (After second moderna covid-19 shot whenever he drinks coffee, dairy, consume red meat, he feels "drunk."). At the time of the report, FEELING DRUNK (After second moderna covid-19 shot whenever he drinks coffee, dairy, consume red meat, he feels "drunk.") outcome was unknown.            No concomitant medications were reported.  Patient also felt like drunk driving. The caller wanted to ask if there was any reversal for this and any information of how often this kind of event was reported. It was unknown if the patient experienced any additional symptoms/events.  No treatment medications were reported.   Reporter did not allow further contact
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Apathy, Fatigue, Feeling abnormal, Illness, Influenza
Clinical narrative: Patient had absolutely lost all motivation; Patient was so sick of being sick; Tired; Patient had described as flu which was same effect after booster but for longer; Patient laid around sick and it was utterly miserable; This spontaneous case was reported by a patient and describes the occurrence of INFLUENZA (Patient had described as flu which was same effect after booster but for longer), FEELING ABNORMAL (Patient laid around sick and it was utterly miserable), APATHY (Patient had absolutely lost all motivation), ILLNESS (Patient was so sick of being sick) and FATIGUE (Tired) in a 55-year-old male patient who received mRNA-1273 (Spikevax) for Emesis.     Concurrent medical conditions included COPD and Blood pressure high.    On 13-Apr-2022, the patient received dose of mRNA-1273 (Spikevax) (Intramuscular use) 1 dosage form. On 14-Apr-2022, the patient experienced INFLUENZA (Patient had described as flu which was same effect after booster but for longer) and FEELING ABNORMAL (Patient laid around sick and it was utterly miserable). On an unknown date, the patient experienced APATHY (Patient had absolutely lost all motivation), ILLNESS (Patient was so sick of being sick) and FATIGUE (Tired). At the time of the report, INFLUENZA (Patient had described as flu which was same effect after booster but for longer) and FEELING ABNORMAL (Patient laid around sick and it was utterly miserable) had not resolved and APATHY (Patient had absolutely lost all motivation), ILLNESS (Patient was so sick of being sick) and FATIGUE (Tired) outcome was unknown.            No concomitant medication was reported.  Patient was laid around sick to stomach and utterly miserable. He had absolutely lost all motivation and would do anything that bought pleasure to him. It was unknown if the patient had any additional medical history, concomitant disease or risk factor. No treatment information was reported.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Deafness, Tinnitus
Clinical narrative: moderate hearing loss; tinnitus; This spontaneous case was reported by a patient and describes the occurrence of DEAFNESS (moderate hearing loss) in a 54-year-old female patient who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) 1 dosage form. On an unknown date, the patient experienced DEAFNESS (moderate hearing loss) (seriousness criterion medically significant) and TINNITUS (tinnitus). At the time of the report, DEAFNESS (moderate hearing loss) and TINNITUS (tinnitus) had not resolved.        The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) was unknown.   For SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use), the reporter did not provide any causality assessments.   No Concomitant medications provided by the reporter.  It was reported that patient was developed Tinnitus and moderate hearing loss over a period of a month.  No treatment medications provided by the reporter.; Reporter's Comments: Company Comments; The benefit-risk relationship of product is not affected by this report
Age: 85.0
Sex: F
Vaccine: COVID19
Symptoms: Death, Lethargy, Malaise
Clinical narrative: Lethargic, very unwell, death
Age: 4.0
Sex: M
Vaccine: DTAPIPV, MMRV
Symptoms: Expired product administered
Clinical narrative: MMRV (ProQuad) was given on 02/25/25 and expired on 02/23/25.
Age: 0.17
Sex: M
Vaccine: DTPPVHBHPB, HEP
Symptoms: Gastrooesophageal reflux disease, Hypotonia, Lethargy, Respiratory arrest, Seizure like phenomena
Clinical narrative: Same day seizure like sounds and body language.  2 days later lethargic., breathing complications. Stopped breathing and was limp..  We went to the ER and spent the night on monitors. It was ruled as acid reflux but he doesn?t have reflux due to nissen surgery which was done at 1month. I brought up how he had his 2 month shots and they said this wouldn?t be from that.
Age: 15.0
Sex: F
Vaccine: HPV9, MNQ
Symptoms: Expired product administered, No adverse event
Clinical narrative: HPV Vaccine expired 01/29/2025 and was given 02/27/2025. No adverse events reported as of 03/03/2025. Parent/guardian notified of expired dose being administered, and advised to bring child in for re-vaccination.
Age: 53.0
Sex: F
Vaccine: TYP
Symptoms: Incorrect dose administered, No adverse event
Clinical narrative: Client took all 4 doses of Oral Typhoid as one dose on 2/13/25. No reported symptoms.
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Graves' disease
Clinical narrative: Diagnosed with Graves Disease.
Age: 2.0
Sex: F
Vaccine: COVID19
Symptoms: Product preparation issue, Pyrexia
Clinical narrative: I administered 0.3 ml of the COVID vaccine to this patient ( concentrated dose ) I didn't know that I had to dilute it with 1.1 ml of saline.  Error was reported, and patient's parent was notified via interpreter. Per patient's parent patient is doing well, and had a fever  of 101.0 F the night of the event, and resolved the next day. Per parents no other adverse reactions were observed. Answered parent's questions to the best of my knowledge,  no other questions at this time.
Age: 93.0
Sex: M
Vaccine: COVID19
Symptoms: Extra dose administered, No adverse event
Clinical narrative: no adverse effects reported, patient got vaccine out of CDC recommended dosing schedule. Last dose was 1/9/25, most recent dose was 3/2/25.
Age: 0.5
Sex: M
Vaccine: COVID19, DTPPVHBHPB, FLU3, PNC20, RV5
Symptoms: Altered state of consciousness, Infantile diarrhoea, Infantile vomiting, Pyrexia
Clinical narrative: Altered level of consciousness 4 months after receiving Vaxelis, prevnar, rotateq, COVID and flu. Some vomiting, Diarrhea and fever. Patient did go to ER when these symptoms occurred in the early afternoon.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Exercise tolerance decreased, Gait disturbance, SARS-CoV-2 antibody test
Clinical narrative: Day of shot - I was very weak and could barely walk.  This lasted for +/- 36 hours.  Have felt weak ever since.  Ability to exercise, decreased over time.  I was taking 5 classes a week and that decreased to a handful a times per year.
Age: 1.0
Sex: M
Vaccine: HEPA, MMRV, VARCEL
Symptoms: Extra dose administered, Wrong product administered
Clinical narrative: Proquad was given instead of MMR so patient received an extra dose of varicella.
Age: 57.0
Sex: F
Vaccine: MMR
Symptoms: Antibody test positive, Contraindication to vaccination, Immunodeficiency
Clinical narrative: Patient was given MMR vaccine while on Skyrizi and therefore immunocompromised.
Age: 74.0
Sex: M
Vaccine: PNC20
Symptoms: Extra dose administered
Clinical narrative: duplicate vaccine 3 years apart.
Age: 60.0
Sex: F
Vaccine: TDAP, TDAP
Symptoms: Mobility decreased
Clinical narrative: Patient said her ROM was limited.  2/25/25 she took generic Aleve and on 2/27/25 she took a generic Aleve.  The ROM is getting better but not 100%.  Wanted the report completed and to ask how long she should have symptoms?
Age: 60.0
Sex: F
Vaccine: TDAP, TDAP
Symptoms: Discomfort, Mobility decreased, Musculoskeletal discomfort, Musculoskeletal stiffness, Pain in extremity
Clinical narrative: Patient said her ROM was limited.  2/25/25 she took generic Aleve and on 2/27/25 she took a generic Aleve.  The ROM is getting better but not 100%.  Wanted the report completed and to ask how long she should have symptoms?
Age: 60.0
Sex: F
Vaccine: TDAP, TDAP
Symptoms: Mobility decreased
Clinical narrative: Shortly after vaccine, I started experiencing pain and muscle stiffness in my upper arm that same morning, which progressively got worse throughout the day. By bedtime that same evening I was not able to move my arm in certain positions  without using my other hand to hold it up. After taking Naproxen every other day, and icing it, it has improved. However, it is 7 days later and I do not have full mobility in that arm yet. I also have discomfort in that whole shoulder that radiates up into lower neck, down to elbow and into shoulder blade.
Age: 60.0
Sex: F
Vaccine: TDAP, TDAP
Symptoms: Discomfort, Mobility decreased, Musculoskeletal discomfort, Musculoskeletal stiffness, Pain in extremity
Clinical narrative: Shortly after vaccine, I started experiencing pain and muscle stiffness in my upper arm that same morning, which progressively got worse throughout the day. By bedtime that same evening I was not able to move my arm in certain positions  without using my other hand to hold it up. After taking Naproxen every other day, and icing it, it has improved. However, it is 7 days later and I do not have full mobility in that arm yet. I also have discomfort in that whole shoulder that radiates up into lower neck, down to elbow and into shoulder blade.
Age: 4.0
Sex: F
Vaccine: DTAPIPV
Symptoms: Erythema, Rash, Skin warm
Clinical narrative: Area of erythema @ 6" laterally @ longest area of redness. 3.5" X 4". Area also had rash noted and was warm to the touch
Age: 3.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: Patient was scheduled vaccine. The vaccine (COVID 6 months- 4 years) was reconstituted on 2/21/25. Vaccine was still in the refrigerator and administered on 2/24/25 to patient's right thigh. I realized the vaccine should have been discarded on 2/22/25, end of the day, but was not. The last dose in the reconstituted vial was administered to patient. The physician was informed of the incident.  No adverse reactions noted during or after the administration of the vaccine. Pfizer was contacted. Pfizer replied they do not have supporting stability data. No additional dose was administered to patient after event.
Age: 58.0
Sex: F
Vaccine: HEPA
Symptoms: Asthenia, Chills, Constipation, Headache
Clinical narrative: After receiving the Hep A vaccine on  the afternoon of Wednesday 2/26/25, I got a headache  3 days later, on the afternoon of 3/1/25. I was very low energy all day on 3/2/25. This morning, 3/3, I woke up uncomfortably constipated.  I am feeling weak and I have chills. As the day progresses, I am starting to feel better.
Age: 84.0
Sex: M
Vaccine: UNK, VARZOS
Symptoms: Seizure
Clinical narrative: 12 hrs after a single dose shingles vaccine he has a seizure event
Age: 41.0
Sex: F
Vaccine: MMR
Symptoms: Induration, Limb mass, Pain in extremity, Skin warm
Clinical narrative: She developed a hot, firm, painful mass in her left upper arm, in the location of the vaccine, but 2 weeks AFTER the vaccine.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Chills, Decreased appetite, Myalgia, Pyrexia
Clinical narrative: Patient did report that a few years ago she had come down with an infection of COVID and as a result held her dose of Humira for some time. She thinks she got Covid in December of 2022 but was not too sure about that. She stated at the time she was vaccinated with the first three doses of Moderna Covid vaccine (two doses in the series for the initial vaccination and a "booster" injection after that. She reported that she no longer gets the COVID vaccines because with all three vaccines she had  muscle pains, chills, loss of appetite, and mild fever that lasted about 2 weeks. She reports that all issues have since resolved, however.
Age: 20.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Anosmia, Antibody test positive, Bedridden, COVID-19, Chest X-ray
Clinical narrative: A previously healthy 24-year-old female with no significant medical history received the Janssen COVID-19 vaccine on March 10, 2021. In October 2021, she contracted COVID-19, experiencing fatigue, congestion, and loss of smell, which has not returned. After recovering, she resumed physical activity, which triggered a relapse of symptoms with increased fatigue. She then received the Pfizer COVID-19 booster on January 22, 2022. Over the following months, she developed persistent fatigue, shortness of breath, chest pain, and post-exertional malaise. In mid-2022, she was diagnosed with POTS after participating in a Long COVID study. By early 2023, her condition worsened significantly, leading to chronic fatigue, muscle pain, and exercise intolerance, requiring extended leave from work. In December 2023, she left her job due to severe fatigue and mobility issues, later requiring a wheelchair.  In July 2024, after a viral illness, her health rapidly declined, with significant weight loss, extreme fatigue, and severe hypersensitivity to light, noise, and touch. She was hospitalized, where workup showed an elevated D-Dimer but no other significant findings. Due to extreme fatigue and an inability to meet caloric needs, a feeding tube was placed. By September 2024, she lost the ability to move on her own and became fully bedbound, requiring 24/7 care. She was readmitted in December 2024, but extensive testing (MRI, CT scan, chest X-ray, ECHO, and labs) was inconclusive aside from continued elevation of D-Dimer. No further treatment was offered. Before discharge, a spike protein test was drawn and later found to be extremely elevated.  Since February 12, 2025, she has been on a spike protein detox protocol, but her condition remains severe, with no significant improvement yet. She continues to experience extreme sensitivities to light, noise, and touch, remains fully bedbound, and requires 24/7 care.  Despite her critical condition, insurance has denied nursing care, categorizing her case as "respite" rather than medical necessity. This has placed a severe burden on her father, who is her primary caregiver while also trying to maintain his job. The family has struggled to secure adequate care, resorting to hiring a nurse, but consistent, professional medical support remains a major challenge.  She will need intensive rehabilitation, including physical and occupational therapy, to regain mobility. Given the timeline of symptoms and deterioration following vaccination and booster administration, this case represents a severe post-vaccine injury with possible long COVID overlap.
Age: 20.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chest pain, Computerised tomogram, Dyspnoea, Echocardiogram, Exercise tolerance decreased
Clinical narrative: A previously healthy 24-year-old female with no significant medical history received the Janssen COVID-19 vaccine on March 10, 2021. In October 2021, she contracted COVID-19, experiencing fatigue, congestion, and loss of smell, which has not returned. After recovering, she resumed physical activity, which triggered a relapse of symptoms with increased fatigue. She then received the Pfizer COVID-19 booster on January 22, 2022. Over the following months, she developed persistent fatigue, shortness of breath, chest pain, and post-exertional malaise. In mid-2022, she was diagnosed with POTS after participating in a Long COVID study. By early 2023, her condition worsened significantly, leading to chronic fatigue, muscle pain, and exercise intolerance, requiring extended leave from work. In December 2023, she left her job due to severe fatigue and mobility issues, later requiring a wheelchair.  In July 2024, after a viral illness, her health rapidly declined, with significant weight loss, extreme fatigue, and severe hypersensitivity to light, noise, and touch. She was hospitalized, where workup showed an elevated D-Dimer but no other significant findings. Due to extreme fatigue and an inability to meet caloric needs, a feeding tube was placed. By September 2024, she lost the ability to move on her own and became fully bedbound, requiring 24/7 care. She was readmitted in December 2024, but extensive testing (MRI, CT scan, chest X-ray, ECHO, and labs) was inconclusive aside from continued elevation of D-Dimer. No further treatment was offered. Before discharge, a spike protein test was drawn and later found to be extremely elevated.  Since February 12, 2025, she has been on a spike protein detox protocol, but her condition remains severe, with no significant improvement yet. She continues to experience extreme sensitivities to light, noise, and touch, remains fully bedbound, and requires 24/7 care.  Despite her critical condition, insurance has denied nursing care, categorizing her case as "respite" rather than medical necessity. This has placed a severe burden on her father, who is her primary caregiver while also trying to maintain his job. The family has struggled to secure adequate care, resorting to hiring a nurse, but consistent, professional medical support remains a major challenge.  She will need intensive rehabilitation, including physical and occupational therapy, to regain mobility. Given the timeline of symptoms and deterioration following vaccination and booster administration, this case represents a severe post-vaccine injury with possible long COVID overlap.
Age: 20.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Fatigue, Fibrin D dimer increased, Gastrointestinal tube insertion, General physical health deterioration, Hyperacusis
Clinical narrative: A previously healthy 24-year-old female with no significant medical history received the Janssen COVID-19 vaccine on March 10, 2021. In October 2021, she contracted COVID-19, experiencing fatigue, congestion, and loss of smell, which has not returned. After recovering, she resumed physical activity, which triggered a relapse of symptoms with increased fatigue. She then received the Pfizer COVID-19 booster on January 22, 2022. Over the following months, she developed persistent fatigue, shortness of breath, chest pain, and post-exertional malaise. In mid-2022, she was diagnosed with POTS after participating in a Long COVID study. By early 2023, her condition worsened significantly, leading to chronic fatigue, muscle pain, and exercise intolerance, requiring extended leave from work. In December 2023, she left her job due to severe fatigue and mobility issues, later requiring a wheelchair.  In July 2024, after a viral illness, her health rapidly declined, with significant weight loss, extreme fatigue, and severe hypersensitivity to light, noise, and touch. She was hospitalized, where workup showed an elevated D-Dimer but no other significant findings. Due to extreme fatigue and an inability to meet caloric needs, a feeding tube was placed. By September 2024, she lost the ability to move on her own and became fully bedbound, requiring 24/7 care. She was readmitted in December 2024, but extensive testing (MRI, CT scan, chest X-ray, ECHO, and labs) was inconclusive aside from continued elevation of D-Dimer. No further treatment was offered. Before discharge, a spike protein test was drawn and later found to be extremely elevated.  Since February 12, 2025, she has been on a spike protein detox protocol, but her condition remains severe, with no significant improvement yet. She continues to experience extreme sensitivities to light, noise, and touch, remains fully bedbound, and requires 24/7 care.  Despite her critical condition, insurance has denied nursing care, categorizing her case as "respite" rather than medical necessity. This has placed a severe burden on her father, who is her primary caregiver while also trying to maintain his job. The family has struggled to secure adequate care, resorting to hiring a nurse, but consistent, professional medical support remains a major challenge.  She will need intensive rehabilitation, including physical and occupational therapy, to regain mobility. Given the timeline of symptoms and deterioration following vaccination and booster administration, this case represents a severe post-vaccine injury with possible long COVID overlap.
Age: 20.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hyperaesthesia, Impaired work ability, Laboratory test, Magnetic resonance imaging, Malaise
Clinical narrative: A previously healthy 24-year-old female with no significant medical history received the Janssen COVID-19 vaccine on March 10, 2021. In October 2021, she contracted COVID-19, experiencing fatigue, congestion, and loss of smell, which has not returned. After recovering, she resumed physical activity, which triggered a relapse of symptoms with increased fatigue. She then received the Pfizer COVID-19 booster on January 22, 2022. Over the following months, she developed persistent fatigue, shortness of breath, chest pain, and post-exertional malaise. In mid-2022, she was diagnosed with POTS after participating in a Long COVID study. By early 2023, her condition worsened significantly, leading to chronic fatigue, muscle pain, and exercise intolerance, requiring extended leave from work. In December 2023, she left her job due to severe fatigue and mobility issues, later requiring a wheelchair.  In July 2024, after a viral illness, her health rapidly declined, with significant weight loss, extreme fatigue, and severe hypersensitivity to light, noise, and touch. She was hospitalized, where workup showed an elevated D-Dimer but no other significant findings. Due to extreme fatigue and an inability to meet caloric needs, a feeding tube was placed. By September 2024, she lost the ability to move on her own and became fully bedbound, requiring 24/7 care. She was readmitted in December 2024, but extensive testing (MRI, CT scan, chest X-ray, ECHO, and labs) was inconclusive aside from continued elevation of D-Dimer. No further treatment was offered. Before discharge, a spike protein test was drawn and later found to be extremely elevated.  Since February 12, 2025, she has been on a spike protein detox protocol, but her condition remains severe, with no significant improvement yet. She continues to experience extreme sensitivities to light, noise, and touch, remains fully bedbound, and requires 24/7 care.  Despite her critical condition, insurance has denied nursing care, categorizing her case as "respite" rather than medical necessity. This has placed a severe burden on her father, who is her primary caregiver while also trying to maintain his job. The family has struggled to secure adequate care, resorting to hiring a nurse, but consistent, professional medical support remains a major challenge.  She will need intensive rehabilitation, including physical and occupational therapy, to regain mobility. Given the timeline of symptoms and deterioration following vaccination and booster administration, this case represents a severe post-vaccine injury with possible long COVID overlap.
Age: 20.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Myalgia, Photophobia, Postural orthostatic tachycardia syndrome, Respiratory tract congestion, Viral infection
Clinical narrative: A previously healthy 24-year-old female with no significant medical history received the Janssen COVID-19 vaccine on March 10, 2021. In October 2021, she contracted COVID-19, experiencing fatigue, congestion, and loss of smell, which has not returned. After recovering, she resumed physical activity, which triggered a relapse of symptoms with increased fatigue. She then received the Pfizer COVID-19 booster on January 22, 2022. Over the following months, she developed persistent fatigue, shortness of breath, chest pain, and post-exertional malaise. In mid-2022, she was diagnosed with POTS after participating in a Long COVID study. By early 2023, her condition worsened significantly, leading to chronic fatigue, muscle pain, and exercise intolerance, requiring extended leave from work. In December 2023, she left her job due to severe fatigue and mobility issues, later requiring a wheelchair.  In July 2024, after a viral illness, her health rapidly declined, with significant weight loss, extreme fatigue, and severe hypersensitivity to light, noise, and touch. She was hospitalized, where workup showed an elevated D-Dimer but no other significant findings. Due to extreme fatigue and an inability to meet caloric needs, a feeding tube was placed. By September 2024, she lost the ability to move on her own and became fully bedbound, requiring 24/7 care. She was readmitted in December 2024, but extensive testing (MRI, CT scan, chest X-ray, ECHO, and labs) was inconclusive aside from continued elevation of D-Dimer. No further treatment was offered. Before discharge, a spike protein test was drawn and later found to be extremely elevated.  Since February 12, 2025, she has been on a spike protein detox protocol, but her condition remains severe, with no significant improvement yet. She continues to experience extreme sensitivities to light, noise, and touch, remains fully bedbound, and requires 24/7 care.  Despite her critical condition, insurance has denied nursing care, categorizing her case as "respite" rather than medical necessity. This has placed a severe burden on her father, who is her primary caregiver while also trying to maintain his job. The family has struggled to secure adequate care, resorting to hiring a nurse, but consistent, professional medical support remains a major challenge.  She will need intensive rehabilitation, including physical and occupational therapy, to regain mobility. Given the timeline of symptoms and deterioration following vaccination and booster administration, this case represents a severe post-vaccine injury with possible long COVID overlap.
Age: 20.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Weight decreased, Wheelchair user
Clinical narrative: A previously healthy 24-year-old female with no significant medical history received the Janssen COVID-19 vaccine on March 10, 2021. In October 2021, she contracted COVID-19, experiencing fatigue, congestion, and loss of smell, which has not returned. After recovering, she resumed physical activity, which triggered a relapse of symptoms with increased fatigue. She then received the Pfizer COVID-19 booster on January 22, 2022. Over the following months, she developed persistent fatigue, shortness of breath, chest pain, and post-exertional malaise. In mid-2022, she was diagnosed with POTS after participating in a Long COVID study. By early 2023, her condition worsened significantly, leading to chronic fatigue, muscle pain, and exercise intolerance, requiring extended leave from work. In December 2023, she left her job due to severe fatigue and mobility issues, later requiring a wheelchair.  In July 2024, after a viral illness, her health rapidly declined, with significant weight loss, extreme fatigue, and severe hypersensitivity to light, noise, and touch. She was hospitalized, where workup showed an elevated D-Dimer but no other significant findings. Due to extreme fatigue and an inability to meet caloric needs, a feeding tube was placed. By September 2024, she lost the ability to move on her own and became fully bedbound, requiring 24/7 care. She was readmitted in December 2024, but extensive testing (MRI, CT scan, chest X-ray, ECHO, and labs) was inconclusive aside from continued elevation of D-Dimer. No further treatment was offered. Before discharge, a spike protein test was drawn and later found to be extremely elevated.  Since February 12, 2025, she has been on a spike protein detox protocol, but her condition remains severe, with no significant improvement yet. She continues to experience extreme sensitivities to light, noise, and touch, remains fully bedbound, and requires 24/7 care.  Despite her critical condition, insurance has denied nursing care, categorizing her case as "respite" rather than medical necessity. This has placed a severe burden on her father, who is her primary caregiver while also trying to maintain his job. The family has struggled to secure adequate care, resorting to hiring a nurse, but consistent, professional medical support remains a major challenge.  She will need intensive rehabilitation, including physical and occupational therapy, to regain mobility. Given the timeline of symptoms and deterioration following vaccination and booster administration, this case represents a severe post-vaccine injury with possible long COVID overlap.
Age: 23.0
Sex: M
Vaccine: VARCEL
Symptoms: Hypersensitivity, Throat tightness, Urticaria
Clinical narrative: started having allergic reaction approx. 5 min after receiving vaccine.   presented with hives on back, chest, face and legs.   stated that his throat seems a little tight.  Fire department was called and they treated    received Benadryl, Solu-Medrol, and Epi IM.   was transported to  ER for evaluation.
Age: 11.0
Sex: M
Vaccine: HPV9, MNQ, TDAP
Symptoms: Swelling face
Clinical narrative: ISOLATED FACIA SWELLING
Age: 27.0
Sex: F
Vaccine: HEP
Symptoms: Urticaria
Clinical narrative: Following morning pt reported waking up with hives on chest that started as mild. Two days after the injection pt reported hives worsening and spreading to chest, stomach, and arms. Pt. took zyrtec with little relief. Pt encouraged to return to facility for treatment. Pt has not returned. Pt told to seek immediate medical attention if hives spread to facial area, difficulty breathing/SOB, or if tongue feels heavy swollen.